Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has earned an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.

Several research firms have commented on BIOVF. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st.

Swedish Orphan Biovitrum Price Performance

BIOVF stock opened at $42.80 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The company has a market capitalization of $15.24 billion, a price-to-earnings ratio of 95.11 and a beta of 0.47. Swedish Orphan Biovitrum has a fifty-two week low of $34.88 and a fifty-two week high of $49.03. The stock has a fifty day moving average of $47.20 and a 200-day moving average of $46.24.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing treatments for rare diseases. Its activities center on conditions in hematology, immunology and specialty care, where patients often have limited treatment options.

Sobi’s portfolio includes therapies for hemophilia and other bleeding disorders, immune-mediated diseases, and rare inflammatory or hematologic conditions. Its products include Elocta and Alprolix for hemophilia, Doptelet for certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for paroxysmal nocturnal hemoglobinuria.